Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen

Cancer Letters

Volumn 112, Issue 2, 1997, Pages 127-133

  So, Felicia V ^a   Guthrie, Najla ^a   Chambers, Ann F ^b   Carroll, Kenneth K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Estrogen receptor; Flavonoids; Human breast cancer cells

Indexed keywords

BAICALEIN; ESTROGEN; ESTROGEN RECEPTOR; FLAVONOID; GALANGIN; GENISTEIN; HESPERETIN; NARINGENIN; THYMIDINE; TRITIUM;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL DIVISION; ESTRADIOL; FLAVONOIDS; GENISTEIN; HUMANS; ISOFLAVONES; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS; TRITIUM;

EID: 0031590969     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(96)04557-0     Document Type: Article

References (15)

1. [1] Shutt, D.A. (1976) The effect of plant oestrogens on animal reproduction, Endeavour, 35, 110-113.
2. [2] Verdeal, K. and Ryan, D.S. (1979) Naturally-occurring estrogens in plant foodstuffs: a review, J. Food Protect., 42, 577-583.
3. [3] Sheehan, D.M. (1995) The case for expanded phytoestrogen research, Proc. Soc. Exp. Biol. Med., 208, 3-5.
4. [4] Kellis, J.T. Jr. and Vickery, L.E. (1984) Inhibition of human estrogen synthetase (aromatase) by flavones, Science, 225, 1032-1034.
5. [5] Soule, H.D., Vazquez, J., Long, A., Albert, S. and Brennan, M. (1973) A human cell line from a pleural effusion derived from a breast carcinoma, J. Natl. Cancer Inst., 51, 1409-1416.
6. [6] Hansen, M.B., Nielsen, S.E. and Berg, K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 119, 203-210.
7. [7] Miksicek, R.J. (1995) Estrogenic flavonoids: structural requirements for biological activity, Proc. Soc. Exp. Biol. Med., 208, 44-50.
8. [8] Clark, J.H., Hardin, J.W., Upchurch, S. and Eriksson, H. (1978) Heterogeneity of estrogen binding sites in the cytosol of the rat uterus, J. Biol. Chem., 253, 7630-7634.
9. [9] Markaverich, B.M. and Clark, J.H. (1979) Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response, Endocrinology, 105, 1458-1462.
10. 3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues, Cancer Res., 44, 1515-1519.
11. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms, Cancer Res., 54, 1458-1464.
12. [12] So, F.V., Guthrie, N., Chambers, A.F., Moussa, M. and Carroll, K.K. (1996) Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr. Cancer, in press.
13. [13] Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M. and Fukami, Y. (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem., 262, 5592-5595.
14. [14] Levy, J., Teuerstein, I., Marbach, M., Radian, S. and Sharoni, Y. (1984) Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin, Biochem. Biophys. Res. Commun., 123, 1227-1233.
15. [15] Ferriola, P.C., Cody, V. and Middleton, E. Jr. (1989) Protein kinase C inhibition by plant flavonoids, Kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol., 38, 1617-1624.